What question did this study set out to answer?

This research aims to evaluate the effectiveness of pumitamig combined with chemotherapy for patients with advanced EGFR-mutated NSCLC after progressing on EGFR TKI.

March 19, 2026Open Access

21P Progression-free survival and overall survival with pumitamig (PD-L1 × VEGF-A bsAb) plus chemotherapy in patients with EGFR-mutated advanced non-small cell lung cancer following progression with EGFR TKI in China: Phase II study results

Puntos clave

This research aims to evaluate the effectiveness of pumitamig combined with chemotherapy for patients with advanced EGFR-mutated NSCLC after progressing on EGFR TKI.
Conducted a single-arm phase II study
Evaluated patients with EGFR-mutated advanced NSCLC
Administered pumitamig in combination with chemotherapy
Measured progression-free survival (PFS) and overall survival (OS)
Showed encouraging progression-free survival rates
Demonstrated overall survival benefits
Indicated antitumor activity in previously treated patients

Resumen

Pumitamig (BNT327/BMS986545) is an investigational bispecific antibody designed to target both PD-L1 and VEGF-A in the tumor and tumor microenvironment that has shown encouraging antitumor activity in combination with chemo in pts with previously treated EGFR-mutated NSCLC. Here, we present PFS and OS data from an ongoing single-arm phase II study of pumitamig + chemo in pts with EGFR-mutated advanced NSCLC who progressed on or after standard EGFR TKI treatment.

Leer artículo completoexternamente

Preguntar a la IA

Me gusta

Guardar

Ver artículo completo